Could a targeted pill help Chinese patients with a specific lung cancer mutation?

Imagine having advanced lung cancer, and doctors find a specific genetic glitch driving it—a mutation in a part of the MET gene called exon 14. This study asked a direct question: could a targeted pill called capmatinib help Chinese patients with this exact situation? The drug works by blocking the faulty MET signal that tells cancer cells to grow. The study enrolled 36 Chinese adults whose cancer had spread (stage IIIB, IIIC, or IV) and who had this MET mutation but not other common mutations like EGFR or ALK. Some patients were new to treatment, while others had tried one or two prior therapies. Everyone took capmatinib pills twice a day. The main goal was to measure how many patients' tumors shrank or disappeared (the overall response rate). The study is now complete, and the results are posted. For patients with this specific genetic driver, the findings could point to a new, targeted way to fight their cancer.